Evidence map›Paper›PMID 36451842›Full record

ArticleERJ open research2022

1-year mortality in lung cancer in France according to key timepoints of care pathways.

Axelle Rivière, Anne Isabelle Lecuyer, Emeline Laurent, Carole Lefebvre, Thierry Lecomte, Elodie Olivier, Delphine Carmier, Laurent Plantier, Leslie Grammatico-Guillon

Abstract read
In one paragraph

Article in ERJ open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Axelle RivièreDepartment of Pulmonology and Pulmonary Function Testing, Teaching Hospital of Tours, Tours, France.
Anne Isabelle LecuyerPublic Health Unit, Epidemiology, Centre-Val de Loire (EpiDclic), Teaching Hospital of Tours, Tours, France.
Emeline LaurentPublic Health Unit, Epidemiology, Centre-Val de Loire (EpiDclic), Teaching Hospital of Tours, Tours, France.
Carole LefebvreOncoCentre, Cancer Network of the Centre-Val de Loire Region, Tours, France.
Thierry LecomteMedical school, University of Tours, Tours, France.
Elodie OlivierCancer Coordination Centre, Teaching Hospital of Tours, Tours, France.
Delphine CarmierDepartment of Pulmonology and Pulmonary Function Testing, Teaching Hospital of Tours, Tours, France.
Laurent PlantierDepartment of Pulmonology and Pulmonary Function Testing, Teaching Hospital of Tours, Tours, France.ORCID https://orcid.org/0000-0002-3426-2936
Leslie Grammatico-GuillonMedical school, University of Tours, Tours, France.ORCID https://orcid.org/0000-0001-7934-8912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: It is unclear whether delays in care affect prognosis of patients with lung cancer. The primary objective of this study was to describe the care pathway of patients diagnosed with lung cancer in a French region. Secondary objectives were to identify markers associated with 1) time from imaging to treatment and 2) with 1-year survival. Methods: In a retrospective cohort study, clinical data from multidisciplinary team meetings for all incident lung cancer cases discussed in 2018 in one French region were matched with medico-administrative data from the National Health Insurance Database. Care pathway time intervals were estimated for small cell lung cancer (SCLC), resected nonsmall cell lung cancer (NSCLC) and unresected NSCLC. Factors associated with delay in the care pathway were identified using linear regression; 1-year survival was analysed using Cox modelling. Results: A total of 685 patients were included. Median time between imaging and treatment was 49 days (interquartile range: 33-73), and was lower in cases of metastatic disease, SCLC and private care. At 1 year, 48% had died (resected NSCLC 12%). In unresected NSCLC, time from diagnostic imaging to first treatment <49 days was associated with a higher risk of death. Time intervals were similar in patients with squamous cell carcinoma Discussion: Time intervals in the care pathways of lung cancer were similar to previous reports, confirming the robustness of retrospective databases. In unresectable NSCLC, rapid care was not associated with better survival.

Identifiers

PMID36451842
PMCPMC9703150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.